An interventional study of Modified Pap test in Cervical Cancer Screening and Cervical Cancer Screening Methods, sponsored by National Taiwan University Hospital. Recruiting at 5 sites in Taiwan. Open to female participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital — 2 open to participants now, 2 under way, 1 of them phase 3. Uterine Cervical Neoplasms · National Taiwan University Hospital.
Among the 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital, this one is the only one that started in 2026, is one of 4 with no phase, and was the 14th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →2 of the 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 20–85 · Women only
By country, each count listing its studies:
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 25 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 850 is above the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 161 across the 6 interventional studies, 300 across the 9 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Pap test plays a crucial role in the early detection of cervical cancer. A pilot single-center randomized controlled trial applied the peak-end concept and added a non-painful step at the end of Pap smear screening, aimed to reduce recalled pain. However, there is still no multicenter study investigating the effect of the modified Pap test on cervical cancer screening participation.
The present project is the first multicenter randomized controlled trial to expand the current scope of the peak-end theory into Pap tests and cervical cancer screening participation by adding a non-painful step at the end of Pap smear screening. Our multidisciplinary team (NTUH Pap Study Group) aims to provide innovative, feasible, and low-cost strategies for cervical cancer screening participation.
Participants: This project expects to include women just before they undergo Pap smear screening at the NTUH Healthcare System. We include eligible women aged 25 or above who have not yet undergone Pap tests from 2026 through 2029. Excluded are those who have ongoing menstruation and those who are pregnant or incapable of understanding the numeric pain scales. Women who have any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or metastatic cancer), previous hysterectomy, previous pelvic surgery or radiotherapy, active vaginal or uterus infection, and analgesic use within 24 hours are excluded due to potential interference with pain intensity. The study protocol was approved by the NTUH Research Ethics Committee. During the recruitment process, every eligible participant is fully informed of this trial's aim, design, and content, except for the intervention details. All participants should provide written informed consent. This study is conducted according to the Declaration of Helsinki and is registered at ClinicalTrials.gov.
Sample size estimation: To achieve 90% statistical power at a two-sided α level of 0.05 for detecting an increase in 3-year cervical cancer screening participation from 30% to 50%, the Year 1 target sample size was estimated at a minimum of 248 participants (180 at NTUH Main Hospital and 68 across branch hospitals) in a 1:1 allocation ratio. We will continue recruiting at least 200 new participants annually from Year 2 (2027) through Year 4 (2029)-setting a cumulative enrollment target of 850 in 2029, planned to run through 2032.
Randomization and blinding: Eligible participants are randomly assigned to either the group receiving the traditional Pap test or the modified Pap test. Computer-generated random numbers are employed for simple randomization with a 1:1 allocation ratio. All participants are kept unaware of any information about group allocation throughout the study period. The operators performing the procedure are not informed by the assistants whether to intervene until a specimen is prepared for cervical cytology. The delayed disclosure of the group allocation until this step ensures that the operators standardize the insertion and opening phases of the Pap test. Cytopathologists who analyze the specimens are blinded to the study.
The modified and traditional Pap tests: All operators experienced in techniques for performing a Pap test should attend workshops for a standard operating procedure. The operators include family physicians and gynecologists. A well-trained research assistant is also responsible for ensuring standardization of procedures to eliminate interoperator variability. During the Pap test, there is a privacy curtain separating participants from the operators. An operator separates the labia with hand and then gently inserts the saline-lubricated speculum sideways. The speculum is rotated 90 degrees and opened to achieve an optimal view of the cervix. Then an operator fixes the speculum to obtain the cell samples by brushes. The above-standardized procedures are the same between the two groups. After preparing a specimen for conventional cytology, an operator loosens the locking nut of the speculum, partially closes the blade, rotates the speculum 90 degrees back to its original insertion orientation, and then removes the speculum in the control group receiving the traditional Pap test. For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds. Participants receiving the modified Pap test do not realize what is going on during the 15-second step because they are behind the privacy curtain. Procedurally, the subsequent addition of a non-painful step after specimen collection does not affect specimen quality.
Interview, Anthropometric Indices, and Anxiety scores: The investigators review the medical records after getting informed consent. In addition to pain evaluations, this project collects information about tobacco use, alcohol consumption, socioeconomic status, marital status, parity, sexually active status, menopause, predicted pain of Pap smears, psychological stress, anxiety score, analgesic use, current medications, and medical history through standardized personal interviews. Body height and weight are measured using a standard stadiometer, and body mass index is calculated. Blood pressure is measured with an electronic sphygmomanometer while the patient is seated after resting for at least five minutes. Psychological stress is assessed using the Brief Symptom Rating Scale -5 (BSRS-5). The BSRS-5 includes items of anxiety, depression, hostility, interpersonal sensitivity, and insomnia measured by a 5-point Likert-type scale of 0-4. Normal, slight, and great mental stress are defined by the sum of BSRS-5 scores ≤ 5, 6-9, and ≥10, respectively. The anxiety score is obtained using the Generalized Anxiety Disorder 7-item (GAD-7). GAD-7 total score for the seven items ranges from 0 to 21 (0-4: minimal anxiety. 5-9: mild anxiety. 10-14: moderate anxiety. 15-21: severe anxiety). Based on a meta-analysis, some experts have recommended considering using a cut-off of 8 to optimize sensitivity without compromising specificity.
Statistical analyses: For the descriptive analyses, values are presented as either numbers (percentages) or mean ± standard deviation. For the univariate analyses, categorical data are compared by the χ2 or Fisher's exact tests. Continuous data are compared using the independent T test. To compare screening uptake between trial groups, the investigators apply an ITT principle, such that outcomes are analyzed according to the trial groups assigned, regardless of whether the participants comply with the intervention components of each trial group. Logistic regression analyses are utilized to estimate the association of the intervention with the probability of 3-year and 1-year uptake of cervical cancer screening. The investigators use the five-region hypothesis test based on odds ratios to test the significant indistinguishability of real-time pain between the two groups for confirming the success of randomization and blinding. The effect sizes of five-minute recalled pain on a 1-5 numeric scale and a 0-10 VAS between the two groups are calculated using Glass's delta. Linear regression analyses are used to estimate the effect of the intervention on scores of 5-minute and 3-month recalled pains. Prespecified subgroup analyses using both linear and logistic regression analyses will be performed and summarized visually using forest plots. Major subgroups of interest include women who are never screened (never underwent Pap tests) and women who are under-screened (have not undergone Pap tests in the past 3 years). Statistical significance levels are determined by two-tailed tests (P \< 0.05). The statistical analyses are performed with SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Modified Pap test
For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds.
3-year cervical cancer screening participation
Defined as attending a Pap test at any clinic before the end of the 3rd subsequent year following study entry
Time frame: 3 years
1-year cervical cancer screening participation
Defined as attending a Pap test at any clinic before the end of the next year following study entry
Time frame: 1 year
5-minute recalled pain intensity on a 1-5 numeric scale and a 0-10 visual analog scale
Recalled pain intensity at 5 minutes after the Pap smear test with evaluation by a 1-5 numeric scale and a 0-10 visual analog scale.
Time frame: 5 minutes after receiving the Pap smear test
3-month recalled pain intensity on a 1-5 numeric scale and a 0-10 visual analog scale
Recalled pain intensity at 3 months after the Pap smear test with evaluation by a 1-5 numeric scale and a 0-10 visual analog scale. To minimize potential propaganda for cervical cancer screening participation, the investigators choose the 3-month interval rather than 6-month or 1-year intervals for long-term pain recollection after Pap tests.
Time frame: 3 months after receiving the Pap smear test
Real time pain during the Pap test using a 1-5 numeric scale
The participants will evaluate and record their pain every five seconds throughout the test with an application on a 1-to-5 numeric scale. The average pain, the maximal pain, and real-time pain at the beginning, first quarter, second quarter, third quarter, and the end of the regular course are compared between the two groups. The investigators will compare the average pain of each group's first and second half of the course. For participants receiving the modified Pap test, the investigators further compare the average pain, the maximal pain, and the last recorded real-time pain of the 15-second step with those of the regular course.
Time frame: Every five seconds throughout the Pap test, up to completion of Pap test
Patient-reported feedback at the end of the study
Patient-reported feedback at the health-service level drives revolutions and innovations. At the end of the study period (after the end of the third follow-up year in participants who do not undergo the 3-year cervical cancer screening after the study entry; or at least one month after the latest Pap test in participants who undergo the 3-year cervical cancer screening after the study entry), all participants will be asked to provide open-ended feedback for future qualitative research on Pap smear screening (detailed in subsequent research proposals). For instance, "Can you tell me more about your thoughts on Pap tests you have undergone these years?" or "What is your opinion on the future of Pap tests?".
Time frame: At the fourth follow-up year in participants who do not undergo the 3-year cervical cancer screening; or between 1 and 12 months after the latest Pap test in participants who undergo the 3-year cervical cancer screening
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Dec 2030, 57 months after the start.
Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 57 months is above that.
Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital →